[
  {
    "ts": "2026-02-13T10:40:02+00:00",
    "headline": "Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets",
    "summary": "Last week saw the newest yearly earnings release from Gilead Sciences, Inc. ( NASDAQ:GILD ), an important milestone in...",
    "url": "https://finance.yahoo.com/news/gilead-sciences-inc-nasdaq-gild-104002543.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "6598793a-43bc-329f-9f82-cd2637f2cc25",
      "content": {
        "id": "6598793a-43bc-329f-9f82-cd2637f2cc25",
        "contentType": "STORY",
        "title": "Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets",
        "description": "",
        "summary": "Last week saw the newest yearly earnings release from Gilead Sciences, Inc. ( NASDAQ:GILD ), an important milestone in...",
        "pubDate": "2026-02-13T10:40:02Z",
        "displayTime": "2026-02-13T10:40:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAEiJmFsYXJTRBPxnneP6w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXB9F2qU7k4qk3_k1DQd9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-inc-nasdaq-gild-104002543.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-inc-nasdaq-gild-104002543.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:57:41+00:00",
    "headline": "BofA Raises PT on Gilead Sciences (GILD) to $162 From $154 – Here’s Why",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical research stocks to buy according to hedge funds. On February 11, BofA lifted the price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $162 from $154, maintaining a Buy rating on the shares. The firm told investors in a post-earnings note that it is confident in […]",
    "url": "https://finance.yahoo.com/news/bofa-raises-pt-gilead-sciences-145741484.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "38c3ce5f-02a2-33a9-89f8-31fb7277108e",
      "content": {
        "id": "38c3ce5f-02a2-33a9-89f8-31fb7277108e",
        "contentType": "STORY",
        "title": "BofA Raises PT on Gilead Sciences (GILD) to $162 From $154 – Here’s Why",
        "description": "",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical research stocks to buy according to hedge funds. On February 11, BofA lifted the price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $162 from $154, maintaining a Buy rating on the shares. The firm told investors in a post-earnings note that it is confident in […]",
        "pubDate": "2026-02-13T14:57:41Z",
        "displayTime": "2026-02-13T14:57:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ha22PhpGlsEhK3tmOzGDVw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CkBvnQJGKRIUyIDAWZszGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bofa-raises-pt-gilead-sciences-145741484.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bofa-raises-pt-gilead-sciences-145741484.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:36:00+00:00",
    "headline": "Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?",
    "summary": "Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.",
    "url": "https://finance.yahoo.com/news/gileads-hiv-portfolio-sustain-growth-143600503.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "ac87d707-61ed-3773-a205-93ac5c80ea41",
      "content": {
        "id": "ac87d707-61ed-3773-a205-93ac5c80ea41",
        "contentType": "STORY",
        "title": "Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?",
        "description": "",
        "summary": "Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.",
        "pubDate": "2026-02-13T14:36:00Z",
        "displayTime": "2026-02-13T14:36:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tEjPL1xniTl4Yv5crLKiVw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3wQ5IrbXljgjZ16xqKRVcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gileads-hiv-portfolio-sustain-growth-143600503.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gileads-hiv-portfolio-sustain-growth-143600503.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T04:43:11+00:00",
    "headline": "3 Overrated  Stocks That Concern Us",
    "summary": "Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.",
    "url": "https://finance.yahoo.com/news/3-overrated-stocks-concern-us-044311757.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "a7108bc4-1e3f-3db7-9276-045634ebf74a",
      "content": {
        "id": "a7108bc4-1e3f-3db7-9276-045634ebf74a",
        "contentType": "STORY",
        "title": "3 Overrated  Stocks That Concern Us",
        "description": "",
        "summary": "Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.",
        "pubDate": "2026-02-13T04:43:11Z",
        "displayTime": "2026-02-13T04:43:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/2e7e270bc6fa6e588fd753e4a11abf71",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VSH Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AHt.fAN9OrC5qY0ZZELj3A--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/2e7e270bc6fa6e588fd753e4a11abf71.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BKCMKZkupOrooausBHnf1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/2e7e270bc6fa6e588fd753e4a11abf71.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-overrated-stocks-concern-us-044311757.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-overrated-stocks-concern-us-044311757.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VSH"
            },
            {
              "symbol": "PANL"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]